R2V™ - Radial Solutions for Interventional Radiology
Radial to Visceral (R2V™) intervention contributes to patients' QOL. It causes fewer bleeding complications than the conventional femoral method.
The RAVI Registry
Have you heard about the outcomes of the radial access in visceral intervention, the RAVI registry? Watch the video and get the details of the registry.
Have you heard about the outcomes of the radial access in visceral intervention, the RAVI registry? Watch the video and get the details of the registry.
Why Choose R2V™
Advantages for patients and healthcare professionals. Get insight from Dr. Marcelo Guimaraes.
Advantages for patients andhHealthcare professionals. Get insight from Dr. Marcelo Guimaraes.
Radial to Visceral
Less-invasive solution for interventional oncology – learn how we push the boundaries in introducing RADIFOCUS™ Glidecath™, the first Terumo device for radial to visceral.
Less-invasive solution for interventional oncology – learn how we push the boundaries in introducing RADIFOCUS™ Glidecath™, the first Terumo device for radial to visceral.
What is R2V™?
Radial to Visceral (R2V™) intervention brings various benefits over Transfemoral Artery Access (TFA), including reduced bleeding complications, easy access site management, improved patient satisfaction and the opportunity for same day discharge. Terumo offers various access devices and embolic agents for R2V™. 1-7
The RAVI Registry
The RAVI registry, a prospective registry on 30-day outcomes with 12 month follow up was conducted to increase the data available on radial access in visceral interventions and to show that radial access is safe and feasible for a wide range of embolization procedures.
Related Contents
